Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis

• Published in: Prostate cancer and prostatic diseases Vol. 23; no. 2; pp. 220 - 231
• Main Authors: Guan, Yupeng, Xiong, Haiyun, Feng, Yupeng, Liao, Guolong, Tong, Tongyu, Pang, Jun
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.06.2020; Nature Publishing Group
• Subjects: 631/67/589/466; 692/53/2422; Analysis; Androstenes - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers; Biomarkers, Tumor - analysis; Biomedical and Life Sciences; Biomedicine; Blood Platelets - pathology; Cancer; Cancer patients; Cancer Research; Care and treatment; Castration; Clinical trials; Confidence intervals; Development and progression; Humans; Indicators; Inflammation; Lymphocytes; Lymphocytes - pathology; Male; Medical prognosis; Meta-analysis; Metastases; Metastasis; Neutrophils; Neutrophils - pathology; Oncology, Experimental; Phenylthiohydantoin - administration & dosage; Phenylthiohydantoin - analogs & derivatives; Platelets; Prognosis; Prostate cancer; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - pathology; Quality assessment; Review Article; Search engines; Survival; East Asia
• ISSN: 1365-7852; 1476-5608
• DOI: 10.1038/s41391-020-0209-3

Background The neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR), as markers of systematic inflammation response, have been reported to be indicators in metastatic castration-resistant prostate cancer (mCRPC), whereas their prognostic values remain conflict. This study was to assess the prognostic value of NLR and PLR in mCRPC patients and to assess the response of abiraterone or enzalutamide through using NLR and PLR. Methods Databases searching was conducted in the PubMed, EMBASE, Google Scholar, and the Cochrane Library for relevant published literature up to October 2019. Data extraction and quality evaluation were performed on the eligible studies. STATA 14.0 software was used to pooled hazard ratios (HRs) and their 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS). Results A total of 3144 mCRPC patients were enrolled from 15 cohort studies in this meta-analysis. The pooled results demonstrated that elevated NLR had a significant association with inferior OS in mCRPC patients treated with abiraterone (HR = 1.63, 95% CI: 1.43–1.85, P  < 0.001) and enzalutamide (HR = 1.48, 95% CI: 1.27–1.72, P  < 0.001), whereas elevated NLR had no significant association with unfavorable PFS treated with abiraterone and enzalutamide, respectively. Elevated PLR had a significant association with an inferior OS (HR = 1.52, 95% CI: 1.16–1.98, P  < 0.001) in mCRPC patients treated with abiraterone. Conclusions NLR and PLR were effective biomarkers for predicting prognosis in mCRPC patients and served as indicators of the efficacy of personalized treatment of mCRPC using abiraterone or enzalutamide. Future, more randomized control trials (RCTs) are needed to investigate the promising value of hematologic parameters.